Activity ID
14798Expires
October 23, 2026Format Type
LiveCME Credit
76Fee
$0CME Provider: Interstate Postgraduate Medical Association
Description of CME Course
MSToronto2026—the 10th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)—is designed to address significant clinical and practice gaps in the diagnosis, management, and long-term care of patients with multiple sclerosis (MS) and related autoimmune neurological disorders. Rapid advances in neuroimaging, biomarker discovery, immunology, and therapeutic strategies have substantially expanded the knowledge base for MS and related demyelinating diseases; however, many clinicians face challenges integrating emerging diagnostic criteria, imaging biomarkers, and evolving treatment approaches into clinical practice. These gaps can lead to delayed diagnosis, uncertainty in disease classification, and variability in treatment decisions.
This educational activity will provide neurologists and other clinicians involved in the care of individuals with MS and related disorders with updated knowledge and practical strategies to improve diagnostic accuracy, interpret emerging imaging and fluid biomarkers, and apply evidence-based treatment approaches across diverse patient populations. Sessions will also address evolving disease classifications, the use of artificial intelligence and advanced imaging in disease monitoring, and the management of related autoimmune neurological conditions including neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), autoimmune encephalitis, and pediatric demyelinating diseases.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
NoNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
Apply updated diagnostic frameworks and emerging biomarkers to improve the early detection and classification of MS and related demyelinating disorders.
Evaluate advances in neuroimaging and molecular imaging technologies to enhance diagnosis, monitoring, and prognostic assessment of MS.
Integrate emerging biological insights, including immunological, genetic, and molecular mechanisms into clinical and research strategies for MS management.
Assess novel therapeutic approaches targeting inflammation, neurodegeneration, and remyelination in MS and related disorders.
Utilize data-driven approaches, including artificial intelligence and machine learning, to improve prognostic modeling and personalized treatment strategies.
Recognize global disparities and social determinants of health influencing MS outcomes and identify strategies to improve access to care and research participation.
Keywords
Multiple Sclerosis, Demyelinating Disease, Neuroimmunology, Biomarkers, Remyelination, Precision Medicine
Competencies
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Professionalism
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Outpatient, Physician Scientists, Rural, Urban
